Avapritinib Is a Game Changer for PDGFRA Exon 18-Mutated GIST

Rachel Narozniak, MA
Published: Saturday, Mar 14, 2020
Michael C.
Heinrich, MD

Michael C. Heinrich, MD

The recent approval of avapritinib (Ayvakit) for advanced PDGFRA exon 18–mutated gastrointestinal stromal tumor (GIST) offers patients a new treatment option for a disease subtype that has not responded to standard therapy. On January 9, 2020, the FDA approved avapritinib for adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including the PDGFRA D842V alteration, the most common exon 18 mutation. Avapritinib is the first therapy cleared for use in this specific patient population.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication